A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
A Disease Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Nicosia, Cyprus, 2006
- Bank of Cyprus Oncology Center
-
-
-
-
-
Athens, Greece, 145 64
- Agioi Anargyroi; 3Rd Dept. of Medical Oncology
-
Athens, Greece, 115 22
- Anticancer Hospital Ag Savas; 1St Dept of Internal Medicine
-
Athens, Greece, 155 62
- IASO General Hospital of Athens
-
Athens, Greece, 115 28
- ARETAIEION UNIVERSITY HOSPITAL; oncology unit
-
Athens, Greece, 115 22
- Anticancer Hospital Ag. Savas ; 2Nd Dept. of Oncology - Internal Medicine
-
Athens, Greece, 151 23
- IASO
-
Athens, Greece, 11525
- 251 Air Force General Hospital-Oncology Clinic
-
Haidari, Greece, 124 62
- Attikon University Hospital; 4th Department of Internal Medicine
-
Piraeus, Greece, 185 47
- Metropolitan Hospital; 2Nd Oncology Clinic
-
Thessaloniki, Greece, 564 29
- Papageorgiou General Hospital; Medical Oncology
-
Thessaloniki, Greece, 546 39
- Theagenio Anticancer Hospital; 3Rd Oncology Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis of HER2-positive unresectable LABC or MBC within 6 months prior to enrollment
Exclusion Criteria:
- None specified
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Participants With HER2-Positive Breast Cancer
Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LABC/MBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site.
Participants will be followed until death, withdrawal of consent or study termination, whichever occurs first.
Study protocol does not specify any particular drug or treatment regimen.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Receiving Each Unique Treatment Regimen Overall
Time Frame: Baseline up to approximately 8 years
|
Baseline up to approximately 8 years
|
|
|
Percentage of Participants Receiving Each Unique Treatment Regimen as First-Line Versus Subsequent-Line Therapy
Time Frame: Baseline up to approximately 8 years
|
Baseline up to approximately 8 years
|
|
|
Percentage of Participants Receiving Each Unique Treatment Regimen Sequence
Time Frame: Baseline up to approximately 8 years
|
Baseline up to approximately 8 years
|
|
|
Progression-Free Survival (PFS)
Time Frame: From start date of anti-cancer treatment regimen to the date of either disease progression or death (up to approximately 8 years)
|
Tumor response will be evaluated by the Investigator according to site-/country-specific medical practice.
Study protocol does not specify any particular method of assessment.
|
From start date of anti-cancer treatment regimen to the date of either disease progression or death (up to approximately 8 years)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
Time Frame: Baseline up to approximately 8 years
|
Baseline up to approximately 8 years
|
|
|
Percentage of Participants Receiving Each Treatment Regimen, by Participant Characteristics
Time Frame: Baseline up to approximately 8 years
|
Baseline up to approximately 8 years
|
|
|
Percentage of Participants Receiving Each Treatment Regimen, by Country/Region
Time Frame: Baseline up to approximately 8 years
|
Baseline up to approximately 8 years
|
|
|
Overall Survival (OS)
Time Frame: From the date of initiation of treatment to the date of death from any cause (up to approximately 8 years)
|
From the date of initiation of treatment to the date of death from any cause (up to approximately 8 years)
|
|
|
Number of Treatment Regimens Received
Time Frame: Baseline up to approximately 8 years
|
Baseline up to approximately 8 years
|
|
|
Percentage of Participants With Complete Response (CR) or Partial Response (PR) - Objective Response Rate (ORR)
Time Frame: From the date of initiation of treatment to the date of disease progression or death from any cause (up to approximately 8 years)
|
Tumor response will be evaluated by the Investigator according to site-/country-specific medical practice.
Study protocol does not specify any particular method of assessment.
|
From the date of initiation of treatment to the date of disease progression or death from any cause (up to approximately 8 years)
|
|
Duration of Response (DOR)
Time Frame: From date of first response (CR or PR) to the date of disease progression (up to approximately 8 years)
|
Tumor response will be evaluated by the Investigator according to site-/country-specific medical practice.
Study protocol does not specify any particular method of assessment.
|
From date of first response (CR or PR) to the date of disease progression (up to approximately 8 years)
|
|
Percentage of Participants by Reasons for Treatment Modification
Time Frame: Baseline up to approximately 8 years
|
Baseline up to approximately 8 years
|
|
|
EuroQoL 5-Dimension 5-Level Questionnaire (EQ-5D-5L) Score
Time Frame: Baseline up to approximately 8 years
|
Baseline up to approximately 8 years
|
|
|
Functional Assessment of Cancer Therapy-Breast (FACT-B) Questionnaire Score
Time Frame: Baseline up to approximately 8 years
|
Baseline up to approximately 8 years
|
|
|
Work Productivity and Activity Impairment-General Health (WPAI-GH) Questionnaire Score
Time Frame: Baseline up to approximately 8 years
|
Baseline up to approximately 8 years
|
|
|
Percentage of Participants With HER2 Retesting
Time Frame: Baseline up to approximately 8 years
|
Baseline up to approximately 8 years
|
|
|
Percentage of Participants With HER2 Overexpression, as Assessed Using In Situ Hybridization or Immunohistochemistry
Time Frame: Baseline up to approximately 8 years
|
Baseline up to approximately 8 years
|
|
|
Healthcare Resource Utilization - Total Healthcare Cost
Time Frame: Baseline up to approximately 8 years
|
Baseline up to approximately 8 years
|
|
|
Healthcare Resource Utilization - Percentage of Participants Who Are Hospitalized
Time Frame: Baseline up to approximately 8 years
|
Baseline up to approximately 8 years
|
|
|
Healthcare Resource Utilization - Length of Hospitalization
Time Frame: Baseline up to approximately 8 years
|
Baseline up to approximately 8 years
|
|
|
Healthcare Resource Utilization - Percentage of Participants With Emergency Room Visit
Time Frame: Baseline up to approximately 8 years
|
Baseline up to approximately 8 years
|
|
|
Healthcare Resource Utilization - Percentage of Participants With Outpatient Visit
Time Frame: Baseline up to approximately 8 years
|
Baseline up to approximately 8 years
|
|
|
Healthcare Resource Utilization - Cost of Disease Related Out-of-Pocket Healthcare Expenditures
Time Frame: Baseline up to approximately 8 years
|
Baseline up to approximately 8 years
|
|
|
Healthcare Resource Utilization - Indirect Disease Related Cost
Time Frame: Baseline up to approximately 8 years
|
Baseline up to approximately 8 years
|
|
|
Healthcare Resource Utilization - Number of Working Hours Missed Among Informal Caregivers due to Disease-Related Caregiving Responsibilities
Time Frame: Baseline up to approximately 8 years
|
Baseline up to approximately 8 years
|
|
|
Healthcare Resource Utilization - Percentage of Participants Receiving Monetary Social Benefits
Time Frame: Baseline up to approximately 8 years
|
Baseline up to approximately 8 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ML28801
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.